"Hämato-Onkologischer Studienkreis MVZ am Klinikum Aschaffenburg / Onkologie"
Welcome,         Profile    Billing    Logout  
 10 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Welslau, Manfred
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
01/22
01/23
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Checkmark [VIRTUAL] Combining New Agents with „3+7“ Chemotherapy in Fit Patients
Recruiting
3
768
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
05/23
09/32
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Checkmark [VIRTUAL] Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial
Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
03/24
03/24
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting
2/3
210
Europe
Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA
University of Giessen
Hairy Cell Leukemia
12/22
12/27
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Recruiting
2
196
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
09/22
09/22
NCT03731832: Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Recruiting
2
82
Europe
MLN9708, Ixazomib 4.0 mg, Pomalidomide 4 MG Oral Capsule, Dexamethasone, Cyclophosphamide
GWT-TUD GmbH
Refractory Multiple Myeloma
12/23
12/24
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

Checkmark PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
Checkmark [VIRTUAL] GENOMIC LANDSCAPE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS
Checkmark [VIRTUAL] Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
Checkmark [VIRTUAL] IVOSIDENIB IMPROVES OVERALL SURVIVAL RELATIVE TO STANDARD THERAPIES IN RELAPSED OR REFRACTORY MUTANT IDH1 AML: RESULTS FROM MATCHED COMPARISONS TO HISTORICAL CONTROLS
Checkmark Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification
More
Recruiting
N/A
Europe
University of Ulm
Acute Myeloid Leukemia (AML), Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)
 
 
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Recruiting
N/A
500
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25

Download Options